Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Protagonist Therapeutics
company
About
Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.
- 101 - 250
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.34M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
$56.79M
Protagonist Therapeutics has raised a total of
$56.79M
in funding over 2 rounds. Their latest funding was raised on
Sep 6, 2018 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 6, 2018 | Grant | $1.45M | 1 |
National Institutes of Health
|
— | Detail |
| May 24, 2017 | Grant | $1.34M | 1 |
National Institutes of Health
|
— | Detail |
| Jul 16, 2015 | Series C | $40M | 2 | — | — | Detail |
| Jun 4, 2013 | Series B | $14M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
2
3
Protagonist Therapeutics is funded by 3 investors.
National Institutes of Health
and Pharmstandard International
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
|
|
— | Series C |
Inbio Ventures
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
